Price range: $136.00 through $680.00
Description
Retatrutide is a revolutionary, investigational once-weekly injectable medication developed by Eli Lilly.
As the first “Triple-G” agonist, it significantly enhances weight loss and glycemic control by targeting three metabolic receptors simultaneously.
Unlike earlier weight-loss treatments that target one or two hormone receptors, retatrutide mimics three naturally occurring hormones:
* The Care Pharmacy
* GLP-1 (Glucagon-like peptide-1): Suppresses appetite, slows stomach emptying, and promotes a feeling of fullness.
* GIP (Glucose-dependent insulinotropic polypeptide): Optimizes insulin secretion and improves fat metabolism.
* GCG (Glucagon): Increases energy expenditure, prompting the body to burn more calories and stored fat.
Primary Uses
Retatrutide is currently completing its final clinical trial phases. The planned primary and secondary uses include:
GoodRx +2
• Obesity Management: Clinical studies show robust weight reduction, with some patient groups achieving weight loss surpassing 24% to 28% of their body weight over trial periods.
GoodRx +1
• Type 2 Diabetes: Delivers strong HbAlc reductions and improves blood sugar regulation.
The Care Pharmacy +1
• Metabolic & Joint Conditions: Being studied for its positive effects on fatty liver disease (NAFLD), obstructive sleep apnea, and knee osteoarthritis.
Retatrutide is the latest weight loss medication that’s currently in phase 3 clinical trials. It contains the active ingredient, retatrutide, and is being developed by the same manufacturer as Mounjaro, Eli Lilly, for the management of obesity and type 2 diabetes. Retatrutide is a triple agonist, targeting the receptors of 3 hormones that can impact appetite, weight, and blood sugar levels, earning it the nicknames the “triple-G” and the “Godzilla” of weight loss jabs
| Quantity | 1, 3, 5, 10 |
|---|
Reviews
There are no reviews yet.